Encouraging activity of bicalutamide and everolimus in castration-resistant prostate cancer (CRPC): Early results from a phase I/II clinical trial

被引：0
|
作者：
Zhang, Hongyong
Wang, Yu
Ghosh, Paramita
Lara, Primo N., Jr.
Pasquinelli, Patricia
Beckett, Laurel
White, Ralph W. deVere
Pan, Chong-Xian
机构：
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/1538-7445.AM10-3720
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3720
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Encouraging activity of bicalutamide and everolimus in castration-resistant prostate cancer (CRPC): Early results from a phase I/II clinical trial
    Pan, C.
    Ghosh, P.
    Suga, J. M.
    Paequinelli, P.
    Beckett, L.
    White, R. Deere
    Lara, P., Jr.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Encouraging activity of bicalutamide and everolimus in castration-resistant prostate cancer (CRPC): Early results from a phase II clinical trial
    Pan, C.
    Ghosh, P.
    Lara, P., Jr.
    Robles, D.
    Beckett, L.
    White, R. de Vere
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [3] Synergistic effects of everolimus and bicalutamide in castration-resistant prostate cancer: Results from a phase I/II clinical trial
    Pan, Chong-xian
    Robles, Daniel
    D'Abronzo, Leandro
    Beggs, Ryan E.
    deVere-White, Ralph
    Lara, Primo
    Ghosh, Paramita M.
    CANCER RESEARCH, 2012, 72
  • [4] Everolimus plus bicalutamide in men with castration-resistant prostate cancer (CRPC): Final results of a phase II trial.
    Pan, Chong-xian
    Chow, Helen
    Ghosh, Paramita
    White, Ralph deVere
    Evans, Christopher P.
    Dall'Era, Marc A.
    Yap, Stanley A.
    Li, Judy
    Beckett, Laurel A.
    Lara, Primo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer
    Chow, Helen
    Ghosh, Paramita M.
    White, Ralph deVere
    Evans, Christopher P.
    Dall'Era, Marc A.
    Yap, Stanley A.
    Li, Yueju
    Beckett, Laurel A.
    Lara, Primo N.
    Pan, Chong-Xian
    CANCER, 2016, 122 (12) : 1897 - 1904
  • [6] Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): Results from a phase I-II clinical trial
    Garcia, Jorge A.
    Elson, Paul
    Tyler, Allison
    Triozzi, Pierre
    Dreicer, Robert
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (01) : 33.e11 - 33.e17
  • [7] Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer
    Nakabayashi, Mari
    Werner, Lilian
    Courtney, Kevin D.
    Buckle, Geoffrey
    Oh, William K.
    Bubley, Glen J.
    Hayes, Julia H.
    Weckstein, Douglas
    Elfiky, Aymen
    Sims, Danny M.
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    BJU INTERNATIONAL, 2012, 110 (11) : 1729 - 1735
  • [8] Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC)
    Scher, H. I.
    Beer, T. M.
    Higano, C. S.
    Taplin, M.
    Efstathiou, E.
    Anand, A.
    Hung, D.
    Hirmand, M.
    Fleisher, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] A phase Ib/II trial of indomethacin and enzalutamide to treat castration-resistant prostate cancer (CRPC).
    Pan, Chong-xian
    Lara, Primo
    Evans, Christopher P.
    Parikh, Mamta
    White, Ralph de Vere
    Dall'era, Marc
    Liu, Chengfei
    Robles, Daniel
    Gao, Allen
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [10] Phase I trial of ASG-5ME in metastatic castration-resistant prostate cancer (CRPC).
    Morris, Michael J.
    Bruce, Justine Yang
    Reyno, Leonard M.
    Anand, Banmeet
    Hartford, Alan
    Jelaca-Maxwell, Kathy
    Lackey, Jacqueline
    Eisenberger, Mario A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345